Merck and SciBrunch Therapeutics have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

George Addona, Senior Vice President—Discovery, Preclinical Development and Translational Medicine, Merck Research Laboratories, said, “Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterised factor in tumor cell growth. This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers.”

Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.

SciBrunch will receive an upfront payment of USD 400 million and is eligible to receive payments associated with the achievement of certain milestones related to development, commercialisation and other activities across multiple indications. The total potential aggregate value of the transaction, including the upfront payment, is USD 2.13 billion.

The transaction has closed.

Tao Hu, Founder, Chairman and Chief Executive Officer, SciBrunch, said, “Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors. This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology. We are excited that Merck, a global leader in oncology, will take SPR2015 forward.”

Merck will record a pre-tax charge of USD 400 million, or approximately USD 0.13 per share, to be included in GAAP and non-GAAP results in the third quarter of 2026 related to this transaction.